NYBCe and CZ Biohub will derive iPSC lines from cord blood's immune cells, creating shared, broadly compatible resources for cell therapy, disease modelling, and AI-driven drug development.
GC Therapeutics (GCTx), a pioneering biotechnology company advancing the next generation of cell-based medicines through its TFome™ (Transcription-Factor-ome) induced pluripotent stem cell (iPSC) ...
Factor Bioscience Inc., a Cambridge-based biotechnology company focused on using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced its participation ...
Explore the major milestones of induced pluripotent stem cell (iPSC) research, from Shinya Yamanaka’s discovery to current ...
Pluristyx, a leading provider of clinical-grade induced pluripotent stem cell (iPSC) solutions, and Qkine, a pioneer in the manufacture of high-purity, animal-free growth factors and cytokines, today ...
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its ...
PHILADELPHIA--(BUSINESS WIRE)--Accelerated Biosciences and Stemmatters are thrilled to announce their strategic partnership aimed at co-developing and co-marketing human induced pluripotent stem cells ...
SEATTLE, April 07, 2026 (GLOBE NEWSWIRE) -- Pluristyx, a leader in advanced induced pluripotent stem cell (iPSC)-based solutions, today announced expansion of its intellectual property portfolio with ...
Avoiding many of the pitfalls associated with conventional iPSC reprogramming methods that can introduce genetic instability, PSXi013 has been reprogrammed using our state-of-the-art, footprint-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results